Potential drug interaction among patients with depression: A systematic review

Yaghoubi, Faezeh; Behzad Basirat, Zahra; Behzad Basirat, Amir Mohamad; Hadei, Nafise; Forouzanfar, Fatemeh; Mousavi, Batool

[Home ] [Archive]

[ فارسی ]

The Neuroscience Journal of Shefaye Khatam

Main Menu

Home

Journal Information

Articles Archive

Guide for Authors

For Reviewers

Ethical Statements

Registration

Site Facilities

Contact us

Indexed by

Search in website

Receive site information

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Articles In Press

Back to the articles list

Back to browse issues page

Potential drug interaction among patients with depression: A systematic review

Faezeh Yaghoubi

, Zahra Behzad Basirat

, Amir Mohamad Behzad Basirat

, Nafise Hadei

, Fatemeh Forouzanfar

, Batool Mousavi ^*

Prevention Department, Janbazan Medical and Engineering Research Center, Tehran, (JMERC), Iran , mousavi.b@gmail.com

Abstract: (129 Views)

Introduction: Depression is a common mental disorder that has serious negative effects on individuals' quality of life. Given the increasing prevalence of depression and the complexities of its treatment, examining drug interactions in patients with this disorder is of particular importance. This study aims to systematically investigate common drug interactions in the treatment of depression and their implications in the Iranian population. Materials and Methods: This study was designed as a systematic review based on the PRISMA statement principles. Keywords related to depression and drug interactions were searched in both domestic and international databases such as Google Scholar and PubMed. Out of 81 initial articles, 52 were examined, and after excluding irrelevant papers, 3 final articles that investigated drug interactions in patients with depression were selected. Results: One study examined outpatient prescriptions (3,000 prescriptions) and two studies analyzed hospitalized patients (1,257 records) regarding drug interactions. Reported rates of drug interactions varied widely, ranging from 22.4% to 99.9%. Most interactions involved the concurrent use of multiple antidepressants, particularly those from the tricyclic antidepressant class, and were classified as serious. Conclusion: This study revealed the limited number of investigations into the prevalence and types of drug interactions in patients with depression in Iran, pointing to the need for further research in this field.

Keywords: Antidepressive Agents, Drug Incompatibility, Mental Disorders, Mood Disorders, Iran

Full-Text [PDF 1369 kb] (19 Downloads)

Type of Study: Systematic Review --- Open Access, CC-BY-NC | Subject: Psychiatry

References

1. Association AP. Understanding Mental Disorders: Your Guide to DSM-5-TR®: American Psychiatric Pub; 2023.

2. Nazari z, foroozandeh e, banitaba m. The Effectiveness of Autobiographical Memory Training on Cognitive Abilities, Emotion Regulation, and Emotional Dysphoria in Depressed Adolescent Girls. The Neuroscience Journal of Shefaye Khatam. 2022; 10(4): 62-70. [DOI:10.52547/shefa.10.4.62]

3. Bandelow B, Schmahl C, Falkai P, Wedekind D, Crockett C, Sackett G, et al. American Psychiatric Association. DSM-5 Task Force.(2013). Diagnostic and statistical manual of mental disorders: Dsm-5 . Washington, DC: American Psychiatric Association. Bachevalier, J., Meunier, M., Lu, MX, & Ungerleider, LG (1997). Thalamic and temporal cortex input to medial prefrontal cortex in rhesus monkeys. Exp Brain Res, 115 (3). Examination of Opioid and Glucocorticoid Receptor Pathways in Rhesus Macaques (Macaca mulatta) Exhibiting Self-Injurious Behaviors. 2017;100(8):11.

4. Isanazar A, Joukar F, Maroufizadeh S, Faraji N, Zeinali T, Soleimani R, et al. Prevalence of depression and associated factors among adults: the PERSIAN Guilan cohort study (PGCS). Journal of Public Health. 2024; 32(7): 1187-95. [DOI:10.1007/s10389-023-01898-1]

5. Mohammad Nia S, Mashhadi A. The Effect of Meaning of life on the Relationship between Attitude toward Substance Abuse and Depression. The Neuroscience Journal of Shefaye Khatam. 2018;6(3):43-51. [DOI:10.29252/shefa.6.3.43]

6. Zhao Y, Yin J, Zhang L, Zhang Y, Chen X. Drug-drug interaction prediction: databases, web servers and computational models. Brief Bioinform. 2023; 25(1). [DOI:10.1093/bib/bbad445]

7. Hines LE, Malone DC, Murphy JE. Recommendations for generating, evaluating, and implementing drug‐drug interaction evidence. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2012; 32(4): 304-13. [DOI:10.1002/j.1875-9114.2012.01024.x]

8. Chen Y, Ding L. Potential drug-drug interactions in outpatients with depression of a psychiatry department. Saudi Pharmaceutical Journal. 2023; 31(2): 207-13. [DOI:10.1016/j.jsps.2022.12.004]

9. Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nature Reviews Disease Primers. 2020; 6(1): 69. [DOI:10.1038/s41572-020-0200-2]

10. Aronson J. Communicating information about drug interactions. British journal of clinical pharmacology. 2007; 63(6): 637. [DOI:10.1111/j.1365-2125.2007.02948.x]

11. Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Archives of Toxicology. 2020; 94: 3381-407. [DOI:10.1007/s00204-020-02885-1]

12. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. Journal of the American Medical Directors Association. 2020; 21(2): 181-7. [DOI:10.1016/j.jamda.2019.10.022]

13. Soherwardi S, Chogtu B, Faizal P. Surveillance of the Potential Drug-Drug Interactions in the Medicine Department of a Tertiary Care Hospital. Journal of Clinical & Diagnostic Research. 2012; 6(7).

14. FDA US. Drug-Drug Interactionces Guidances: U.S. FOOD & DRUG ADMINISTRATION; 2024 [Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-interactions-relevant-regulatory-guidance-and-policy-documents.

15. Cole S, Kerwash E, Andersson A. A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. Drug Metabolism and Pharmacokinetics. 2020; 35(1): 2-11. [DOI:10.1016/j.dmpk.2019.11.005]

16. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences. 2021; 22(23): 12808. [DOI:10.3390/ijms222312808]

17. Koohpayezadeh F, Motamdi M, Eskandari H, Farrokhi N. Effectiveness of a psychological-educational package based on the logo therapy on loneliness and self-efficacy of retired teachers. Journal of Gerontology. 2019; 4(2): 24-33. [DOI:10.29252/joge.4.1.24]

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021; 372:n71. [DOI:10.1136/bmj.n71]

19. Semnani KM, Saeedi M, Mashinchi MI. Evaluation of Anti-depressant Drugs Interactions in Insured Prescriptions in Anzali in 1379. Journal Of Guilan University Of Medical Sciences. 2002; 11(41): 26-33.

20. Esteghamat SS, Esteghamat SS, Bastani F, Kazemi H, Koulivand P, Bayan L, Gorji A. Potential drug interactions in war-injured veterans with Psychaitric disorders. Iranian Journal of War and Public Health. 2012; 4(13): 23.

21. Gorji A, Gharakhani M, Jahromi SR, Sadeghian H, Faghihzadeh S, Kazemi H, et al. Multiple drug interactions in war-injured veterans. Iranian Journal of War and Public Health. 2010; 2(8): 23.

22. Dagnew EM, Ergena AE, Wondm SA, Sendekie AK. Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia. BMC Pharmacology and Toxicology. 2022; 23(1): 88. [DOI:10.1186/s40360-022-00630-1]

23. Satoskar R, Rege N, Bhandarkar S. Pharmacology and pharmacotherapeutics: Elsevier Health Sciences; 2017.

24. Coelho PV, Brum Cde A. Interactions between antidepressants and antihypertensive and glucose lowering drugs among patients in the HIPERDIA Program, Coronel Fabriciano, Minas Gerais State, Brazil. Cad Saude Publica. 2009; 25(10): 2229-36. [DOI:10.1590/S0102-311X2009001000013]

25. Dongre K, Jungo A, Späni S, Zysset Y, Leuppi-Taegtmeyer A. Disease-Drug Interactions Requiring Special Attention. Praxis (Bern 1994). 2022; 111(12): 700-5. [DOI:10.1024/1661-8157/a003923]

26. Mousavi B, Seyed Hoseini Davarani SH, Soroush M, Jamali A, Khateri S, Talebi M, Montazeri A. Quality of life in caregivers of severely disabled war survivors. Rehabil Nurs. 2015; 40(3): 139-47. [DOI:10.1002/rnj.159]

27. Zheng WY, Richardson L, Li L, Day R, Westbrook J, Baysari M. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. European journal of clinical pharmacology. 2018; 74(1): 15-27. [DOI:10.1007/s00228-017-2357-5]

28. Mousavi B, Maftoon F, Soroush M, Mohammad K, Majdzadeh R. Health care utilization and expenditure in war survivors. Archives of Iranian medicine. 2020; 23(4Suppl1): S9-S15. [DOI:10.34172/aim.2020.s3]

29. Mousavi B, Soroush M, Maftoon F, Mohammad K, Ayoubian A. Satisfaction of supplementary insurance for medicinal services in war survivors in Iran. Med J Islam Repub Iran. 2019; 33: 66. [DOI:10.47176/mjiri.33.66]

30. Lau L, Bagri H, Legal M, Dahri K. Comparison of clinical importance of drug interactions identified by hospital pharmacists and a local clinical decision support system. The Canadian Journal of Hospital Pharmacy. 2021; 74(3): 203. [DOI:10.4212/cjhp.v74i3.3147]

31. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Archives of internal medicine. 2006;166(9): 955-64. [DOI:10.1001/archinte.166.9.955]

32. Woody C, Ferrari A, Siskind D, Whiteford H, Harris M. A systematic review and meta-regression of the prevalence and incidence of perinatal depression. Journal of affective disorders. 2017; 219: 86-92. [DOI:10.1016/j.jad.2017.05.003]

33. World Health Organization Depressive disorder (depression) 2023 [https://www.who.int/news-room/fact-sheets/detail/depression#:~:text=An%20estimated%203.8%25%20of%20the,among%20women%20than%20among%20men.

34. Tahan M, Saleem T, Zygoulis P, Pires LVL, Pakdaman M, Taheri H, Ebrahimpour M. A systematic review of prevalence of Depression in Iranian patients. Neuropsychopharmacol Hung. 2020; 22(1): 16-22.

35. Yalçın N, Özdemir N, Cak Esen HT, Çengel Kültür SE, Demirkan K. Potential drug‐drug interactions with psychotropic drugs in paediatric inpatients: A cross‐sectional study. International journal of clinical practice. 2021; 75(6): e14107. [DOI:10.1111/ijcp.14107]

36. Lai LL, Alvarez G, Dang L, Vuong D, Ngo V, Jo Y, Koh L. Prevalence and trend of potential drug-drug interaction among children with depression in US outpatient settings. Journal of Pharmaceutical Health Services Research. 2019; 10(4): 393-9. [DOI:10.1111/jphs.12320]

37. Chen Y, Ding L. Potential drug-drug interactions in outpatients with depression of a psychiatry department. Saudi Pharm J. 2023; 31(2): 207-13. [DOI:10.1016/j.jsps.2022.12.004]

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Back to the articles list

Back to browse issues page

Persian site map - English site map - Created in 0.06 seconds with 47 queries by YEKTAWEB 4710